Hepatitis B inactive carriers: clinical course and outcomes

Area of Science:

• Hepatology
• Virology
• Oncology

Background:

• Hepatitis B virus (HBV) inactive carriers are defined by specific criteria: hepatitis B e antigen (HBeAg)-negative status, normal alanine aminotransferase (ALT) levels, and HBV DNA ≤ 10000 copies/mL.
• Understanding the clinical course and potential risks associated with HBV inactive carriers is crucial for patient management.

Purpose of the Study:

• To investigate the clinical significance of transient elevations in ALT and HBV DNA levels in patients with inactive HBV infection.
• To assess the long-term outcomes, including hepatocellular carcinoma (HCC) development, in a cohort of inactive HBV carriers.

Main Methods:

• A prospective follow-up study involving 146 inactive HBV carriers from January 1989 to January 2012.
• Regular monitoring included ALT and HBV DNA measurements every 6-12 months, alongside surveillance for HCC.

Main Results:

• During an average follow-up of 8 years, most patients maintained inactive carrier status.
• Transient elevations in ALT and HBV DNA were observed in a significant portion of patients, with most ALT levels returning to baseline.
• While a small percentage experienced HBsAg loss or reactivation, two patients developed HCC, highlighting the persistent risk.

Conclusions:

• Transient fluctuations in ALT and HBV DNA in inactive HBV carriers typically have a favorable prognosis and minimal clinical impact.
• Despite the generally good outlook, ongoing surveillance for HCC remains essential due to the continued risk of liver cancer development in this population.